Clinical trials: Diabetes (DM)
Type 2 Diabetes Mellitus
Efficacy and Safety of DLBS1033 in Subjects With Type 2 Diabetes Mellitus
This is a prospective, double-blind, randomized, and controlled study. The investigational product, DLBS1033 at a dose of 490 mg thrice daily or placebo, will be given for an 8-week course of therapy.
- Trial name
- NCT01865474
- Testing
- DLBS1033
- Where
- Indonesia
- Volunteers
- 122 people
- Sponsor
- Dexa Medica Group
Type 2 Diabetes Mellitus
Korean Observational Study to Evaluate the Efficacy and Safety of Anagliptin Switching From Other DPP4is in type2 DM
This study was designed as a non-interventional, single-group, open-label, multicenter observational study for patients with type 2 diabetes in the real world clinical setting.
- Trial name
- SSUG (NCT04267601)
- Testing
- Anagliptin
- Where
- South Korea
- Volunteers
- 2,448 people
- Sponsor
- JW Pharmaceutical
Type 2 Diabetes Mellitus
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan
Primary Objective: To compare LixiLan to lixisenatide in glycated hemoglobin (HbA1c) change from baseline to Week 26 in patients with type 2 diabetes mellitus.
- Trial name
- LIXILAN JP-O1 (NCT02749890)
- Testing
- Insulin glargine/Lixisenatide (HOE901/AVE0010), Lixisenatide (AVE0010), Oral anti-diabetic drugs
- Where
- 61 sites in Japan
- Volunteers
- 321 people
- Sponsor
- Sanofi
Disbiosis, Obesity
Limosilactobacillus Fermentum CRL 1446 - CONICET CASASCO
This research study aims to determine if a probiotic called Limosilactobacillus fermentum CRL 1446 can improve the health of people at risk for cardiovascular disease.
- Conditions
- Disbiosis, Obesity, Overweight (BMI > 25), Hypertension (Without Type 2 Diabetes Mellitus)
- Trial name
- NCT07530575
- Testing
- Limosilactobacillus fermentum 1446 CRL CONICET 2.20E+9 CFU
- Where
- 2 sites in Argentina
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- PINER Pastor Manfredi Winery
RELATED REGISTRY SEARCH
HF Prevalence and Evolution of HF in DM II Patients at High Risk
This is an epidemiological, single-country, multicenter, 2-year prospective cohort study based on both primary and secondary data collection, which will include a representative sample of 300 eligible T2DM patients managed in…
- Trial name
- HF-LanDMark (NCT04482283)
- Where
- 10 sites in Greece
- Volunteers
- 245 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Trial to Evaluate the Efficacy and Safety of Gemigliptin Compared With Placebo Added on Insulin Alone or on Insulin in Combination With Metformin in Type 2 DM (ZEUS II Study)
The objective of this study is to evaluate the efficacy and safety of gemigliptin 50 mg orally administered once daily for 24 weeks compared with placebo in patients with type 2 diabetes mellitus who have inadequate glycemic…
- Trial name
- NCT02831361
- Testing
- Gemigliptin, Metformin, Diet/exercise questionnaire
- Volunteers
- 290 people
- Sponsor
- LG Life Sciences
Diabetes (DM), Diabetes (Insulin-requiring, Type 1 or Type 2)
MiniMed Fit Payload Wear Pediatric Study
The purpose of this study is to assess MiniMed Fit Payload adhesive components in different wear locations over a 7-day period to support development of the future commercialized patch pump in participants 7-17 years of age.
- Conditions
- Diabetes (DM), Diabetes (Insulin-requiring, Type 1 or Type 2), Diabetes in Children, Diabetes in Adolescence
- Trial name
- NCT07675161
- Testing
- MiniMed Fit Payload adhesive components
- Where
- 5 sites in United States
- Volunteers
- 59 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetics Mellitus Type 1, Diabetes Mellitus Type 2
Testing the Effect of the InsuPad Device in Daily Life Conditions
This is the test protocol for the InsuPad device. The aim of the study is to show economical benefit when using the InsuPad device, by testing the effect of the InsuPad device on reducing injected insulin dose while keeping the…
- Trial name
- NCT01594801
- Testing
- InsuPad
- Where
- 9 sites in Germany
- Volunteers
- 145 people
- Sponsor
- Insuline Medical Ltd.
Type 2 Diabetes Mellitus
Diabetes Mellitus Type 2 Basal Insulin Dosing Requirements Study
The main purpose of this study is to determine the number of daily basal insulin rate changes that are needed to achieve short-term near normal glucose control in insulin pump patients with type 2 diabetes
- Trial name
- NCT00874809
- Testing
- CGMS with an insulin pump using rapid acting insulin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Diabetes Care Center
Glycemia, Hypertension
Effect of PATient Education Related to CV Risk factOrs in Type 2 Diabetes Mellitus(Patrol).
This study will address the proportion of achievement patients in treatment target goal on glycemic control, hypertension and hyperlipidemia according to ADA 2008 guideline, among outpatients coming to the Korean primary care…
- Conditions
- Glycemia, Hypertension, Hyperlipidemia
- Trial name
- PATROL (NCT00891124)
- Where
- 7 sites in South Korea
- Volunteers
- 4,045 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
Specific Clinical Experience Investigation for Long-term Use of Exenatide (Byetta Subcutaneous Injection)
The purpose of this investigation is to describe general safety profile of type II Diabetes Mellitus (DM) Japanese patients under exenatide therapy in real world medical practices
- Trial name
- NCT01817569
- Where
- 46 sites in Japan
- Volunteers
- 2,948 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Dyslipidemia
Prevalence of Subclinical Atherosclerosis and Its Associated Factors in Hyperlipidemic Korean Adults With Diabetes
This study is to investigate correlation between Carotid Intima Media Thickness (cIMT) and several factors such as; hs C-reactive protein (CRP), HbA1c, lipid profile in Korean diabetic patients with atherosclerosis.
- Trial name
- ALTO (NCT01264263)
- Where
- 3 sites in South Korea
- Volunteers
- 181 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 1
TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM)
The purpose of this study is to optimize several multi-dose regimens of otelixizumab, determine the highest biologically active dose, evaluate biomarkers and surrogates of efficacy, and to evaluate the effects of each multi-dose…
- Trial name
- TTEDD (NCT00451321)
- Testing
- Otelixizumab
- Where
- 17 sites in United States, Canada
- Volunteers
- 88 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes, Diabetes (DM)
Detecting Type 2 Diabetes From Voice
The goal of this observational study is to learn if computer analysis of voice recordings can detect Type 2 diabetes in adults. The main questions it aims to answer are: Can advanced voice analysis accurately identify…
- Conditions
- Type 2 Diabetes, Diabetes (DM), T2DM, T2DM (Type 2 Diabetes Mellitus)
- Trial name
- NCT07421921
- Where
- United Kingdom
- Volunteers
- 7,319 people, healthy volunteers welcome
- Sponsor
- Thymia Limited
Diabetes Mellitus Type 2
ENhancing Outcomes Through Goal Assessment and Generating Engagement in Diabetes Mellitus
The purpose of this study is to evaluate whether a combination of pharmacist-delivered patient engagement techniques improves disease control and medication adherence among patients with poorly-controlled diabetes compared with…
- Trial name
- ENGAGE-DM (NCT02910089)
- Testing
- Shared Decision Making
- Where
- United States
- Volunteers
- 1,400 people
- Sponsor
- AstraZeneca
Hypercholesterolemia
Ezetimibe (+) Simvastatin vs. Atorvastatin Comparative Study in DM or Metabolic Syndrome Patients (0653A-093)
An efficacy and safety study of ezetimibe (+) simvastatin compared to atorvastatin at week 6 in diabetics or metabolic syndrome patients in Korea.
- Trial name
- NCT00157924
- Testing
- simvastatin (+) ezetimibe, atorvastatin
- Volunteers
- 190 people
- Sponsor
- Organon and Co
Type 2 Diabetes Mellitus
A Study to Efficacy and Safety of CWP-0403 in Type 2 Diabetes Mellitus Patients
This trial is to evaluate the efficacy and safety of CWP-0403 at 100 mg or 200 mg twice daily compared with placebo in type 2 diabetic patients with inadequate glycemic control by diet therapy or combination of diet and exercise…
- Trial name
- CWP-DIANA-301 (NCT01529528)
- Testing
- Anagliptin
- Where
- South Korea
- Volunteers
- 117 people
- Sponsor
- JW Pharmaceutical
Peripheral Arterial Disease (PAD), Diabetes Mellitus (DM)
The Efficacy and Safety of REX-001 to Treat Ischemic Rest Pain in Subjects With CLI Rutherford Category 4 and DM
This trial is a pivotal, placebo-controlled, double-blind, parallel-group, adaptive trial conducted in subjects with DM and CLI Rutherford Category 4.
- Conditions
- Peripheral Arterial Disease (PAD), Diabetes Mellitus (DM), Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT03111238
- Testing
- REX-001
- Where
- 15 sites in Czechia, Germany and 4 more
- Volunteers
- 3 people
- Sponsor
- Ixaka Ltd
Diabetes Mellitus, Type 2
Foxiga Korea Local Phase 4 Study
To evaluate the effect of dapagliflozin on body composition in Korean T2DM subjects.12-month, randomised, open-label, parallel-group, multi-centre phase IV study.
- Trial name
- BEYOND (NCT02564926)
- Testing
- Dapagliflozin, Glimepiride
- Where
- 14 sites in South Korea
- Volunteers
- 125 people
- Sponsor
- AstraZeneca
Peripheral Arterial Disease (PAD), Diabetes Mellitus (DM)
The Efficacy and Safety of REX-001 to Treat Ischemic Ulcers in Subjects With CLI Rutherford Category 5 and DM
This trial is a pivotal, placebo-controlled, double-blind, parallel-group, adaptive trial conducted in subjects with DM and CLI Rutherford Category 5.
- Conditions
- Peripheral Arterial Disease (PAD), Diabetes Mellitus (DM), Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT03174522
- Testing
- REX-001
- Where
- 15 sites in Czechia, Hungary and 4 more
- Volunteers
- 49 people
- Sponsor
- Ixaka Ltd